肺癌患者血清CA125Ⅱ测定的临床意义  

Analysis of Clinical Value of Serum CA125 Ⅱ in Lung Cancer Patients

作　　者：江旭[1] 于仁波[1] 梅昆[1] 刘彤[1] 

机构地区：[1]青岛市肿瘤医院,266042

出　　处：《青岛医药卫生》2000年第2期97-98,共2页Qingdao Medical Journal

摘　　要：目的 探讨CA125Ⅱ测定对肺癌的诊断和治疗的价值。方法 采用免疫放射分析法(IRMA)。结果 各组肺癌CA125Ⅱ水平均显著高于肺良性疾患组织和正常对照组(P<0.05及P<0.01);CA125Ⅱ阳性率分别是鳞癌36.1％,腺癌71.4％,未分化癌41.7％,整体肺癌阳性率53.3％;CA125Ⅱ阳性检出率与临床分期有关,Ⅰ期6/20(30％),Ⅱ期13/30(43.3％),Ⅲ期15/22(68.2％),Ⅳ14/18(77.8％);Ⅲ、Ⅳ期阳性率明显高于Ⅰ、Ⅱ期(P<0.01)。结论 CA125Ⅱ测定对肺癌特别是肺腺癌的诊断有较高的价值,对于临床分期,疗效观察以及预后判断,治疗方案的选择等有一定的意义。Objective To investigate the clinical value of serum CA125 Ⅱ in lung cancer. Methods Use immunora-diometoric assay (IRMA). Results The serum CA125 Ⅱ level in lung cancer was significantly higher than in benign diseases ol lung and normal control group (P<0. 05 or P<0. 01). The CA125 Ⅱ positive rate in squamous cell lung cancer,adenocarcinoma and undifferinated cell carcinoma was 36. 1% ,71. 4% and 41. 7% respectively. The overall positive rate was 53. 3%. The CA125 Ⅱ positive rate was related to the clinical stage of the disease,in stage I was 6/20(30%),in stage Ⅱ was 13/30(43. 3%),in stage 333 was 15/22(68. 2%),in stage Ⅴ was 14/18(77. 8%). The positive rate in stage Ⅲ . Ⅳ was signficantly higher than in stage Ⅰ .Ⅱ (P<0. 01). Conclusion The serum CA125 Ⅱ level was a good aspect for the diagnosis of lung cancer espe-cialy for adenocarcinoma. It could also assist to clinical staging,predict treatment result and prognosis of the disease.

关 键 词：肺癌 CA125Ⅱ 免疫放射分析(IRMA) 

分 类 号：R734.2[医药卫生—肿瘤]